Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
10/06/2026 16:33
BRIEF-Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint June 10 (Reuters) - Alphamab Oncology 9966.HK:
PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsAlphamab climbs most in over 8 weeks on progress of breast cancer treatment
Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
Brief: Alphamab Oncology Says CEO Buys 554,000 Shares On June 4
Brief: Alphamab Oncology Says Phase III KN026-004 Study Enrolls 521 Patients And Meets Primary Endpoint
Brief: Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint